Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 2,382 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Questionnaire 1 Clear all

Conditions: Erdheim-Chester Disease
Interventions: Dabrafenib Mesylate, Quality-of-Life Assessment, Questionnaire Administration, Trametinib Dimethyl Sulfoxide; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Keratoconus
Interventions: Rotating Scheimpflug camera (Pentacam HR); Diagnostic Test
Lead sponsor: University Hospital, Geneva; Other
Eligibility: 6 Years to 23 Years
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Obesity-Related Malignant Neoplasm
Interventions: Educational Activity, Educational Intervention, Informational Intervention, Questionnaire Administration, Support Group Therapy; Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 10 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer
Interventions: Flexible Fiber-based CO2 Laser, Quality of Life forms, electrocautery resection and quality of life forms; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • New York, New York + 1 more

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Melanoma, Stage II, Melanoma Stage IV
Interventions: Assessment, Biospecimen Collection, Quality-of-Life Assessment, Questionnaire Administration; Behavioral · Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), HIV
Interventions: No intervention; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Migraine
Interventions: Pet Scan, MRI scan, Quantitative Sensory Testing (QST); Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Ovarian Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years to 74 Years · Female only
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2028
U.S. locations: 12
States / cities: Miami, Florida • Des Moines, Iowa • Minneapolis, Minnesota + 8 more

Conditions: Human Papillomavirus-Negative Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma, Resectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma, Resectable Head and Neck Squamous-cell Carcinoma
Interventions: Biospecimen Collection, Chemotherapy, Decitabine, External Beam Radiation Therapy, Questionnaire Administration, Surgical Procedure; Procedure · Drug · Radiation + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Malignant Neoplasm
Interventions: Netupitant, Palonosetron Hydrochloride, Questionnaire Administration; Drug · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
Interventions: BCG Solution, Cystoscopy, Docetaxel, Gemcitabine, Home Health Encounter, Mitomycin, Questionnaire Administration; Biological · Procedure · Drug + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Parkinson Disease
Interventions: Home Visit Program, Caregiver Mentorship Program; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 40 Years and older
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
Interventions: FACT-B, Goserelin, Anastrozole, Exemestane, Fulvestrant, Tamoxifen, Archived tissue collection; Behavioral · Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 70 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hepatitis C
Interventions: PREP-C, Modified ECHO, Patient Telemedicine Questionnaire; Behavioral
Lead sponsor: Jens Rosenau; Other
Eligibility: 18 Years to 99 Years
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Nicotine Use Disorder, Smoking Cessation, Smoking Cessation Intervention
Interventions: Enhanced Courage to Quit; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 26 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
Interventions: Avelumab, Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 271
States / cities: Phoenix, Arizona • Auburn, California • Berkeley, California + 214 more

Conditions: Neuroendocrine Tumors
Interventions: 68Ga-DOTATATE; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatous Vasculitis, Temporal Arteritis, Giant Cell Arteritis, Granulomatosis With Polyangiitis, Wegener Granulomatosis, Henoch Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Urticarial Vasculitis
Interventions: Online Questionnaire; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Transgender Persons
Interventions: Survey; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 15 Years to 21 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Healthy Adults
Interventions: Nasal Spray; Other
Lead sponsor: Akita Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus
Interventions: Proton beam therapy, Patient-Reported Outcome Measures; Radiation · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer, Stage I Rectal Cancer, Stage II Rectal Cancer, Stage III Rectal Cancer
Interventions: questionnaire administration, laboratory biomarker analysis, Standard Dietary Intervention, Intensified Dietary Intervention, Low glycemic load, Medium Glycemic Load; Other · Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Breast Carcinoma
Interventions: Fingolimod, Fingolimod Hydrochloride, Questionnaire Administration; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Rochester, Minnesota • Columbus, Ohio • Richmond, Virginia

Conditions: Esophagogastric Cancer
Interventions: Survey, Intra-oral camera, Optional Salvia sample; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

The K-Map Study, Global Prevalence of KC

Parent and Family Oriented Support Interventions for the Facilitation of Weight Loss in African American Families

A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

COVID-19 Recovery Study: Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV

Structural and Molecular Neuroplasticity in Migraine

Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women

Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

In-Home Care for Patients With Parkinson's Disease

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Community Access, Retention in Care, and Engagement for Hepatitis C Treatment

Implementation of Tobacco Cessation Programming at Community Behavioral Health Sites

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective

Journey of Patients With Vasculitis From First Symptom to Diagnosis

Research Participation With Transgender and Gender-Diverse Youth

Feasibility, Acceptability, and Safety of a Drug-Free Nasal Spray in Frontline Healthcare Workers

Proton Beam Therapy in the Treatment of Esophageal Cancer

Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer

Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer

A Study of Tooth Erosion in People With Esophagogastric Cancer